Seattle Genetics, Inc. (JOBS) Gets Stock Offering Totalling $136 Million

Published: Aug 14, 2009

Bookmark and Share

xconomy.com -- Seattle Genetics, the Bothell, WA-based developer of antibody drugs for cancer, said today that underwriters of its stock offering have exercised their options to buy more shares, which makes the deal worth a total of $136 million. JP Morgan and Goldman Sachs led the offering, which also included Needham & Co., Oppenheimer & Co., RBC Capital Markets, and William Blair & Co. The company, as we described in a feature story earlier this week, has attracted interest partly because it is six months ahead of schedule in the pivotal study of its experimental drug for Hodgkin’s disease.

Back to news